Maryland Prescription Drug Affordability Board

​Drugs Referred to Stakeholder Council​

The comment period for Drugs Referred to the Stakeholder Council begins April 10, 2024. Comments are due by COB, Friday, May 10, 2024. Comments may be submitted to comments.pdab@maryland.gov with “Drugs Referred to the Stakeholder Council Comment" in the subject line.

Drugs Referred to the Stakeholder Council

Comments Received for Drugs Referred to Stakeholder Council

• Boehringer Ingelheim
  
• Mark Varner
  
• Chase Brexton​​​ (Letter #1)
  
• AFSCME Maryland
• Maryland Tech Council
  
• ICER
  
• ICER- Final Evidence Report- Moderate to Severe Plaque Psoriasis
  
• ICER- Final Evidence Report- Atopic Dermatitis
  
• ICER- Final Evidence Report- Treatment of Asthma associated with Type 2 Inflammation
  
• ​​Chase Brexton (Letter #2)
  
• AARP Maryland
  
• Maryland Legislative Coalition
• Mid-Atlantic Association of Community Health Centers
• Gilead
• Community Access National Network
• AbbVie
• Global Coalition on Aging
  
• National Eczema Association
  
• Equality Federation
• Chase Brexton (Letter #3)
• HealthHIV
  
• ​​​​​Richard DeBenedetto, PharmD, MS, AAHIVP
• Sanofi
• Novo Nordisk
  
• Takeda
  
• Lilly​​​

Therapeutic Alternatives

The comment period for Therapeutic Alternatives (for Drugs Referred to the Stakeholder Council) begins April 10, 2024 for the therapeutic alternatives linked below. Comments are due by COB, Friday, May 10, 2024. Comments may be submitted to comments.pdab@maryland.gov with “Therapeutic Alternatives" in the subject line.

• Biktarvy Proposed Therapeutic Alternatives
• Farxiga Proposed Therapeutic Alternatives
• Jardiance Proposed Therapeutic Alternatives
• Trulicity Proposed Therapeutic Alternatives
• Ozempic Proposed Therapeutic Alternatives
• Vyvanse Proposed Therapeutic Alternatives
  

The comment period for Therapeutic Alternatives for Drugs Referred to the Stakeholder Council begins April 11, 2024 for the therapeutic alternatives linked below. Comments are due by COB, Monday, May 13, 2024. Comments may be submitted to comments.pdab@maryland.gov with “Therapeutic Alternatives" in the subject line.

• Dupixent Therapeutic Alternatives
• Skyrizi Therapeutic Alternatives
  

Additional Information

• Drugs Referred to the Stakeholder Council- Dashboard (Corrected/Posted 5/15/2024)
  
• This is a sample database that includes non-proprietary data and data that has been approved for public display​
  ​
  ALL COMMENTS WILL BE POSTED AS THEY ARE RECEIVED.